Streetbeat News

Earnings

NUVB

Nuvation Bio reported its Q2 2024 GAAP EPS at $(1.89), which is significantly lower than the $(0.06) estimate. The company also reported sales of $1.435 million.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:14 pm

AMC

AMC Entertainment Holdings shares are trading lower after the company reported Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:13 pm

CAR

Avis Budget Group, Inc. (NASDAQ:CAR) is set to release its Q2 earnings on Aug. 5, 2024. Analysts expect a significant drop in EPS from $11.01 to $2.58 and project revenue of $3.14 billion. Recent analyst ratings show mixed sentiments with price target cuts from Goldman Sachs, B of A Securities, Susquehanna, and Morgan Stanley, while Northcoast Research upgraded the stock to Buy.

Portfolio Pulse from Avi Kapoor

August 05, 2024 | 12:11 pm

COHN

Cohen & Co (AMEX:COHN) reported a significant decline in its Q2 financial performance, with a 403.33% increase in losses per share and a 52.16% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:08 pm

LCID

LI

NIO

RIVN

TSLA

XPEV

Chinese EV startups Nio, XPeng, and Li Auto have significantly increased their R&D spending, with Nio and XPeng reporting net losses. In comparison, Tesla and BYD have lower R&D expenses as a percentage of revenue but higher vehicle deliveries. American startups Rivian and Lucid also reported high R&D costs and net losses.

Portfolio Pulse from Anan Ashraf

August 05, 2024 | 12:06 pm

BBDO

Bank Bradesco (NYSE:BBDO) reported a 14.29% increase in Q2 EPS to $0.08 and a 24.53% increase in sales to $3.28 billion compared to the same period last year.

Portfolio Pulse from saritha@benzinga.com

August 05, 2024 | 12:05 pm

XGN

Exagen Inc. has increased its FY24 revenue outlook to at least $57 million, up from the previous outlook of at least $55 million. The company also expects its adjusted EBITDA loss to be better than $12 million, an improvement from the prior outlook of better than negative $18 million.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:05 pm

KRYS

Krystal Biotech has reiterated its financial guidance for FY24, expecting Non-GAAP R&D and SG&A expenses to be between $150 million and $175 million. This guidance does not include stock-based compensation due to its inherent uncertainty.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:03 pm

GSL

Global Ship Lease (NYSE:GSL) reported Q2 2024 adjusted EPS of $2.46, beating the estimate of $2.29. Sales were $175 million, surpassing the $171.713 million estimate and showing a 7.97% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:02 pm

XGN

Exagen (NASDAQ:XGN) reported Q2 2024 GAAP EPS of $(0.16), beating the $(0.34) estimate, and sales of $15.064M, surpassing the $13.133M estimate. This represents a significant improvement in both earnings and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:01 pm